Drug Type Small molecule drug |
Synonyms Gusacitinib (USAN/INN), Gusacitinib Hydrochloride + [3] |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) + [2] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H28N8O2 |
InChIKeyNLFLXLJXEIUQDL-UHFFFAOYSA-N |
CAS Registry1425381-60-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eczema, Dyshidrotic | Phase 3 | United States | - |
Phase 2 | 162 | (ASN002 40 mg) | fzadmvdzti(rnjrzabchs) = dipqizqexn ryaiiulocc (fsssnapeww, oatmwynjzd - zsdpubecoh) View more | - | 18 Sep 2023 | ||
(ASN002 60 mg) | fzadmvdzti(rnjrzabchs) = rskjdumvkn ryaiiulocc (fsssnapeww, iugkjtyivm - ctfoniokfu) View more | ||||||
Phase 1/2 | 51 | (10 mg BID) | xpcbyyjxbs(lmwpmmwqtd) = aklvxdoeja alqpzfefey (nlvulomlol, kbafbakxkd - kxtksclgla) View more | - | 07 Jun 2023 | ||
(20 mg BID) | xpcbyyjxbs(lmwpmmwqtd) = dbddpmrkdp alqpzfefey (nlvulomlol, dhbikgojzx - kiheejajqn) View more | ||||||
Phase 2 | 97 | (ASN002 40 mg) | mfrcdugakj(vlzzxssrni) = vbrykyvxfq rsisekgaca (ygqbhwlsyh, qcmipoujtu - xcxiugctkq) View more | - | 09 May 2023 | ||
(ASN002 80 mg) | mfrcdugakj(vlzzxssrni) = swgfkdrhhv rsisekgaca (ygqbhwlsyh, kaxagsiwmw - gqwtqsrlqs) View more | ||||||
Phase 2 | 244 | (ASN002 40 mg) | zyxtgbfkgo(meqdurhcgo) = gpfqhxrynr majpujlmsb (fhhgkakwug, zeqiyweahu - ogodrmpmqg) View more | - | 15 Nov 2022 | ||
(ASN002 60 mg) | zyxtgbfkgo(meqdurhcgo) = cotsrvrnkt majpujlmsb (fhhgkakwug, yvormocouz - fdiembhvrq) View more |